psoriasis
Conditions
Interventions
Psoriasis observation group:no
Sponsors
People’s Hospital of Xinjiang Uygur Autonomous Region
Eligibility
Sex/Gender
All
Age
6 Years to 80 Years
Inclusion criteria
Inclusion criteria: Male or female patients aged 6-80 years (including upper and lower limits) (based on the day of signing the informed consent form (ICF)); 2. Weight = 50 kg, BMI value above 25 kg/m2; 3. Patients with moderate or severe plaque psoriasis in the baseline period are defined as follows: BSA = 10%, PASI = 12, and sPGA score = 3; 4. Meet the diagnostic criteria for metabolic syndrome (Guidelines for the Prevention and Treatment of Type 2 diabetes in China (2020 Edition), diabetes Branch of the Chinese Medical Association): ? Abdominal obesity: female waist circumference>85cm, male waist circumference>90cm; ? Hyperglycemia: fasting blood glucose = 6.1mmol/L or blood glucose = 7.8mmol/L 2h after glucose load and/or those who have been diagnosed with diabetes and treated; ? Hypertension: blood pressure = 130/85mmHg and/or those who have been confirmed with hypertension and treated; ? fasting triglyceride (TG) = 1.70mmol/L; ? fasting HDL-C cholesterol<1.04mmol/L. Those with 3 or more of the above criteria can be diagnosed; If it is a woman of childbearing age, she should not be pregnant or breastfeeding; 6. Patients must be able to communicate well with researchers and comply with the requirements of the study, and sign written informed consent. 7. Patients must voluntarily and be able to complete the research procedures and follow-up examinations.
Exclusion criteria
Exclusion criteria: When screening or baseline, patients with psoriasis other than chronic plaque type (such as pustular, erythrodermic, and drip psoriasis); 2. At baseline, it is drug-induced psoriasis (i.e. new onset or exacerbation of psoriasis caused by beta blockers, calcium channel inhibitors, or lithium); 3. Suffering from other active skin diseases or skin infections (bacteria, fungi, or viruses) that may affect the clinical evaluation of psoriasis; 4. There are factors such as mental abnormalities or visual or hearing impairments that hinder the normal conduct of the questionnaire survey; 5. Refusal to participate or inability to cooperate in completing blood and stool collection during the informed consent process.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis area and severity index, PASI;Body Surface Area, BSA;Physician's global assessment, PGA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnostic indicators of metabolic syndrome;dermatology life quality index,DLQI; | — |
Countries
China
Contacts
Public ContactYuan Ding
People’s Hospital of Xinjiang Uygur Autonomous Region
Outcome results
None listed